Site icon Market Globalist

Where Could Petros (PTPI) Stock Be Going With Yesterday’s 19% Rise?

NAK

NAK

The dollar volume of the leading provider of therapeutics for men’s health Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) on Thursday was approximately 1.13 million, with over 0.29 million shares trading and a closing price of $3.89. A positive weekly performance of 21.56% was recorded by Petros stock over the past 5 sessions, and the stock’s price on March 25th improved nearly 19.33%.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

The public owns 9.69 million shares of PTPI stock and among those, 6.11 million shares have been available for trading. This surge in PTPI stock occurred despite the lack of any relevant news, but the previous development shared this month may give a better idea of where Petros will go.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

Where Petros is heading to?

Petros is dedicated to providing the best possible men’s healthcare through the identification, development, acquisition, and commercialization of innovative therapeutics related to men’s health issues. Among those are erectile dysfunction, endothelial dysfunction, psychosocial problems, Peyronie’s disease, hormonal health, substance abuse, and other illnesses.

Stendra (avanafil) was used to investigate endothelial function in men suffering from erectile dysfunction (ED). The findings were released last week by Petros Pharmaceuticals in a publication.

Finally,

A previous label expansion was carried over by Petros (PTPI) from Stendra’s FDA approval date in 2013 to its FDA approval date in 2014, resulting in Stendra being the only prescription ED medication in the marketplace which will be putting PTPI ahead of the peers.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Exit mobile version